International Society for the Study of Women's Sexual Health

NEWS

FDA announced a Public Advisory Committee Meeting

FDA announced a Public Advisory Committee Meeting to review the approval of flibanserin for hypoactive sexual desire disorder (HSDD) in women on June 4, 2015. Should you wish to submit your written comments or request time at the public microphone, the deadline is a week away. Please find all details in the Federal Register Notice by clicking on this link. - -

Save the Date

ISSWSH Fall Course 2019
November 14-16, 2019   206 days left
DoubleTree Hilton Hotel, Scottsdale, AZ - USA
Read more...

ISSWSH Annual Meeting 2020
March 5-8, 2020   318 days left
Renaissance Orlando at Seaworld, Orlando, FL, USA

Latest Tweets

New studies indicate less risk of flibanserin and alcohol. #addyi #flibanserin @SproutPharma https://t.co/TTnjvQbO9x ISSWSH
New review looking at sexual dysfunction among PCOS (polycystic ovarian syndrome) patients demonstrates that sexual… https://t.co/JuQ7yxxDxE ISSWSH
Suffering from #painfulsex? Read about one patients Journey and evidence based resources. #patientadvocatehttps://t.co/OBSu6FINOh ISSWSH

Contact Details

ISSWSH Executive Office
14305 Southcross Dr
Suite 100
Burnsville, MN 55306
USA

Phone: +1 (952) 683 9025
Fax: +1 (952) 314 8212
Email: This email address is being protected from spambots. You need JavaScript enabled to view it.

Follow us on Twitter!